NCT06688383

Brief Summary

This is a nationwide prospective observational study to assess the overall clinical anastomotic leakage rate after right hemicolectomy for cancer, to detect the independent risk factors for AL, and to develop a clinical prediction model to estimates of the probability of the occurrence of an AL after surgery. Since this is a multicenter prospective study, the Division of Surgical Oncology and Digestive Surgery from the University of Turin, Department of Oncology, AOU San Luigi Gonzaga di Orbassano will be the Coordinator Center of the study, Ethics committee approves will be requested before the implementation of this study. Italian high-volume colorectal surgery centers members of SICO (The Italian Society of Oncological Surgery) have agreed to participate as collaborators of this study, notification and revision from their local ethics committee will be requested as well. A certified general surgeon with a large experience in the preoperative, operative, and postoperative management of patients with colorectal cancer has been identified to coordinate the study in each center. Id information of the potential collaborators is specified in the section "Trial Setting". Once the study is activated, eligible patients (or a representative) must provide written, informed consent before any study procedures occur. No intervention or modification of the habitual clinical practice is planned All data will enter into a database provided by the promoting center. There are three main sections of data collection for each patient:

  • Preoperative: baseline, disease and demographics.
  • Operative: details about the surgery, anastomosis construction and enterotomy closure.
  • Follow-up: outcomes data about the early (within 30 postoperative day) and late postoperative course (31 th - 60th postoperative day) and pathology report. The definition of AL is based on the presence of clinical signs (pain, fever, tachycardia, peritonitis, feculent or enteric drainage, purulent drainage, postoperative ileus, abscess, septicemia, and/or organ failure) with radiographic signs (fluid collections, gas containing collections at CT scan) suggestive of AL and-or intraoperative or autopsy findings (gross enteric spillage, anastomotic disruption). The absence of AL will be assumed by a normal postoperative course and the absence of symptoms suggestive of AL with or without radiologic confirmation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,839

participants targeted

Target at P75+ for all trials

Timeline
1mo left

Started Jan 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Jan 2021Jun 2026

Study Start

First participant enrolled

January 1, 2021

Completed
3.8 years until next milestone

First Submitted

Initial submission to the registry

October 17, 2024

Completed
28 days until next milestone

First Posted

Study publicly available on registry

November 14, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Expected
Last Updated

November 14, 2024

Status Verified

November 1, 2024

Enrollment Period

4.4 years

First QC Date

October 17, 2024

Last Update Submit

November 12, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • overall rate of AL

    defined as the total cases of patients with clinical signs or symptoms of AL (pain, fever, tachycardia, peritonitis, feculent or enteric drainage, purulent drainage, postoperative ileus, abscess, septicemia, and/or organ failure), any radiological findings suggestive of AL (fluid collections, gas containing collections at CT scan) or intraoperative or autopsy findings (gross enteric spillage, anastomotic disruption), expressed in percentage. \[time frame: from 1st to 30th postoperative day\]. And identify the main associated factors through a multivariate model regression.

    from 1st to 30th postoperative day

Secondary Outcomes (4)

  • overall morbidity

    from 1st to 60 postoperative day

  • operative mortality

    within 30 postoperative days

  • Length of stay.

    from date of surgery up to 200 days

  • reoperation

    from 1st to 60 postoperative day

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients from all participating centers older than 18 years, males or females, with the diagnosis of primary right colon cancer including the cecum, ascendent, liver flexure, and proximal third of the transverse colon, in both emergency and elective settings, with the indication of RH, referred as to the resection of a portion of the distal ileum, cecum, ascending colon, and proximal to the mid-transverse colon, with intraperitoneal or extraperitoneal primary handsewn or mechanical ileocolic anastomosis by minimally invasive(robotic or laparoscopic) or open approach.

You may qualify if:

  • Patients from all participating centers older than 18 years, males or females, with the diagnosis of primary right colon cancer including the cecum, ascendent, liver flexure, and proximal third of the transverse colon, in both emergency and elective settings, with the indication of RH, referred as to the resection of a portion of the distal ileum, cecum, ascending colon, and proximal to the mid-transverse colon, with intraperitoneal or extraperitoneal primary handsewn or mechanical ileocolic anastomosis by minimally invasive(robotic or laparoscopic) or open approach.

You may not qualify if:

  • Long steroid treatment for any cause.
  • Right colon resection for benign disease.
  • History of supra-mesocolic space radiotherapy.
  • Inflammatory bowel disease (Crohn's disease and ulcerative colitis). No healthy volunteers are accepted.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

San Luigi Gonzaga

Orbassano, Piedmont, 10043, Italy

RECRUITING

Central Study Contacts

Rossella Reddavid, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PHD

Study Record Dates

First Submitted

October 17, 2024

First Posted

November 14, 2024

Study Start

January 1, 2021

Primary Completion

June 1, 2025

Study Completion (Estimated)

June 1, 2026

Last Updated

November 14, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will share

Locations